Insilico Medicine: Difference between revisions
Updated |
Added valuation: Est. $1B+ (AI drug discovery leader) |
||
| Line 11: | Line 11: | ||
== Activity (April 2026) == | == Activity (April 2026) == | ||
Hosted "Pharma AI Spring Kickoff 2026" webinar on AI drug discovery applications.<ref>News-Medical (Apr 11, 2026)</ref> CEO discussed practical AI applications in pharma R&D, emphasizing real results over hype.<ref>STAT News (Apr 1, 2026)</ref> | Hosted "Pharma AI Spring Kickoff 2026" webinar on AI drug discovery applications.<ref>News-Medical (Apr 11, 2026)</ref> CEO discussed practical AI applications in pharma R&D, emphasizing real results over hype.<ref>STAT News (Apr 1, 2026)</ref> | ||
== Funding == | |||
'''Valuation:''' Est. $1B+ (AI drug discovery leader) | |||
== See Also == | == See Also == | ||
Latest revision as of 07:42, 14 April 2026
What They Do[edit]
AI-driven drug discovery company using deep learning for target identification, molecule generation, and clinical trial optimization. One of the most established AI pharma companies globally.
Activity (April 2026)[edit]
Hosted "Pharma AI Spring Kickoff 2026" webinar on AI drug discovery applications.[1] CEO discussed practical AI applications in pharma R&D, emphasizing real results over hype.[2]
Funding[edit]
Valuation: Est. $1B+ (AI drug discovery leader)